Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cholesterol/Lipid Disorders
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cholesterol/Lipid Disorders
    TopAbstracts in Cholesterol/Lipid Disorders 11/26/2009 - (DGNews)
    Statins Can Reduce Risk of Major Cardiovascular Events in Healthy Women: Presented at AHA - (DGDispatch)
    Trends in High Levels of Low-Density Lipoprotein Cholesterol in the United States, 1999-2006 - (JAMA)
    Atorvastatin Improves Renal Function in Patients With Heart Disease, Metabolic Syndrome: Presented at AHA - (DGDispatch)
    Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness - (N Engl J Med)

    News archive

     Recent webcasts/CME - Cholesterol/Lipid Disorders
      Medication Use for Diabetes, Hypertension, and Hypercholesterolemia from 1988-1994 to 2001-2006
      Diabetes and the Heart: Cardiac Care for the Patient with Diabetes: Clinical Horizons
      High-Density Lipoprotein and the Epidemiology of Coronary Heart Disease
      Diabetes Management - Pearls of Lipid Control
      Initiating and Monitoring Statin Therapy

      Webcasts/CME archive

       Recent cases - Cholesterol/Lipid Disorders
        Lipemic Serum In Hyperlipidemic Pancreatitis
        There May be a Link Between Intrahepatic Cholestasis of Pregnancy and Familial Combined Hyperlipidaemia: A Case Report
        Marked Aortic Valve Stenosis Progression After Receiving Long-Term Aggressive Cholesterol-Lowering Therapy Using Low-Density Lipoprotein Apheresis in a Patient With Familial Hypercholesterolemia
        Acute Myocardial Infarction in an 18 Year Old South Indian Girl with Familial Hypercholesterolemia: A Case Report
        Eruptive Xanthomas and Acute Pancreatitis in a Patient with Hypertriglyceridemia

        Cases archive
          




        my personal edition > cholesterol/lipid disorders > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Nilvadipine Lowers Low-Density Lipoprotein in Hypertensive Patients: Presented at ISA

        By Eurona Earl Tilley

        KYOTO, JAPAN -- October 1, 2003 -- Nilvadipine, a lipophilic calcium channel blocker, decreases low-density lipoprotein (LDL) cholesterol levels in patients with hypertension, according to study results presented here September 30th at the 13th International Symposium on Atherosclerosis.

        Dr. Werner O. Richter, Institute for Lipid Metabolism und Haemorrheology, Windach, Germany, and colleagues evaluated the blood pressure, heart rate, body weight, total cholesterol, LDL, high-density lipoprotein (HDL) cholesterol, and triglyceride levels of patients at baseline, 3, 6, 9, and 12 months.

        Of the 170 participants, 23 had a baseline LDL level of less than 130 mg/dL, 57 had a baseline level between 130 mg/dL and 160 mg/dL, 58 had a baseline between 160 mg/dL and 190 mg/dL, and 32 had a baseline level higher than 190 mg/dL.

        Dr. Richter illustrated that a progressive decrease in LDL level was seen throughout the study, with a 6.7% mean decrease after 3 months, a 10.5% decrease after 6 months, a 15.8% decrease after 9 months, and a 18.3% decrease after 12 months.

        Men had a 16.8% decrease in mean LDL level, and women a 20.0% decrease. The effect of nilvadipine on LDL levels was dose dependent. A dose of 16 mg/day caused a 22.8% decrease, while 8 mg/day caused a 17.5% decrease.

        The higher the initial level of LDL, the more significantly nilvadipine was able to reduce LDL levels. Raw data show that after 12 months of treatment, patients who had an initial level of less than 130 mg/dL had a final mean level of 113.5 mg/dL. Those who had a baseline level greater than 190 mg/dL had a final mean level of 157.2 mg/dL.

        Dr. Richter stated that nilvadipine is effective for reducing LDL-cholesterol levels. Since many patients with hypertension also have elevated LDL levels, the additional lipid-lowering benefits of nilvadipine may further reduce the coronary risk of these patients.

        Although nilvadipine was shown to have a dose-dependent effect on LDL levels in patients with arterial hypertension, additional controlled clinical trials are required to further evaluate the effects of this drug.


        [Study title: Effect of Nilvadipine on Serum Lipoproteins in Patients With Hypertension. Abstract 2P-0584]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send